Preview

Нефрология

Расширенный поиск

ПРОБЛЕМА СООТНОШЕНИЯ ПОЛЬЗЫ И РИСКА ТЕРАПИИ СРЕДСТВАМИ, СТИМУЛИРУЮЩИМИ ЭРИТРОПОЭЗ, ПРИ ДИАБЕТИЧЕСКОЙ НЕФРОПАТИИ

https://doi.org/10.24884/1561-6274-2010-14-3-32-36

Полный текст:

Аннотация

Более 20 лет для коррекции анемии у пациентов с хронической болезнью почек (ХБП) применяются средства, стимулирующие эритропоэз (ССЭ). В настоящее время в России доступно несколько препаратов из группы ССЭ: эпоэтин-α (эпокрин, эральфон, эпрекс), эпоэтин-β (рекормон), эпоэтин-ω (эпомакс), дарбэпоэтин-α (аранесп), пегилированный эпоэтин-β (мирцера). Несмотря на то, что изучению эффективности терапии ССЭ и её влияния на прогрессирование ХБП и сердечно-сосудистых осложнений было посвящено большое количество исследований, до сих пор отсутствует единое мнение относительно показаний к проведению терапии ССЭ, оптимальных терапевтических схем и целевых уровней гемоглобина.

Об авторах

И. Ю. Пчелин
Санкт-Петербургский государственный университет, г.Санкт-Петербург
Россия

кафедра факультетской терапии медицинского факультета

197227, Санкт-Петербург, СПбГУ, медицинскиий факультет, пр. Испытателей, д. 6., к. 1, кв. 112; Тел.: +79213614700.



А. Н. Шишкин
Санкт-Петербургский государственный университет, г. Санкт-Петербург
Россия
кафедра факультетской терапии медицинского факультета


Л. П. Коробицын
ООО ”Протеиновый контур”, г. Санкт-Петербург
Россия


Список литературы

1. Elliott S, Pham E, Macdougall IC. Erythropoietins: A common mechanism of action. Exp Hematol 2008; 36: 1573-1584

2. Шестакова МВ, Дедов ИИ. Сахарный диабет и хроническая болезнь почек. ООО «Медицинское информационное агентство», М., 2009; 355-358

3. Kestenbaum B, Kimmel PL, Malozowski S et al. Reevaluating erythropoiesis-stimulating agents. N Engl J Med 2010; 362: 1742-1743

4. Bosman DR, Winkler AS, Marsden JT et al. Anaemia associated with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 2001; 24: 495-499

5. Thomas MC, MacIsaac RJ, Tsalamandris C et al. Unrecognized Anemia in Patients with Diabetes: A cross-sectional survey. Diabetes Care 2003; 26: 1164-1169

6. McGill JB, Bell DSH. Anemia and the role of erythropoietin in diabetes. J Diabetes Complications 2006; 20: 262-272

7. McCullough PA, Bakris GL, Owen WF. Slowing the progression of diabetic nephropathy and its cardiovascular consequences. Am Heart J 2004; 48: 243-251

8. Najafian B, Mauer M. Progression of diabetic nephropathy in type 1 diabetic patients. Diabetes Res Clin Pract 2009; 83: 1-8

9. Hahr AJ, Molitch ME. Diabetes, Cardiovascular Risk and Nephropathy. Cardiol Clin 2010. In press

10. Conti AA, Minelli M, Gensini GF. Global management of high risk patients: Integrated primary cardiovascular prevention in diabetics. International Congress Series 2007; 1303: 10-20

11. Pfeffer MA, Burdmann EA, Chen CY et al. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis 2009; 54: 59-69

12. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032

13. Wright RJ, Kanagasundaram NS, Quinton R et al. Darbepoetin alfa and chronic kidney disease. N Engl J Med 2010; 362: 653-654

14. Marsden PA. Treatment of Anemia in Chronic Kidney Disease — Strategies Based on Evidence. N Engl J Med 2009; 361: 2089-2090

15. Drueke TB, Locatelli F, Clyne N et al. Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia. N Engl J Med 2006; 355: 2071-2084

16. Singh AK, Szczech L, Tang KL et al. Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease. N Engl J Med 2006; 355: 2085-2098

17. Zoppini G, Targher G, Chonchol M et al. Anaemia, independent of chronic kidney disease, predicts all-cause and cardiovascular mortality in type 2 diabetic patients. Atherosclerosis 2010; 210: 575-580

18. Joss N, Patel R, Paterson K et al. Anaemia is common and predicts mortality in diabetic nephropathy. QJM 2007; 100: 641-647

19. Unger EF, Thompson AM, Blank MJ. Erythropoiesis-Stimulating Agents – Time for a reevaluation. N Engl J Med 2010; 362: 189-192

20. Vaziri ND, Zhou XJ. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol Dial Transplant 2009; 24: 1082-1088

21. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Selective modulation of the erythropoietic and tissue-protective effects of erythropoietin: Time to reach the full therapeutic potential of erythropoietin. Biochim Biophys Acta 2007; 1776: 1-9

22. Ruifrok WT, Boer RA, Westenbrink BD et al. Erythropoietin in cardiac disease: New features of an old drug. Eur J Pharmacol 2008; 585: 270-277

23. Miura T, Miki T, Nishihara M et al. Molecular mechanisms of cardiomyocyte protection against ischemia/reperfusion injury by erythropoietin (EPO) receptor activation. J Mol Cell Cardiol 2006; 41: 1043-1044

24. Cooij MA, Groenendaal F, Kavelaars A et al. Neuroprotective properties and mechanisms of erythropoietin in ‘in vitro’ and ‘in vivo’ experimental models for hypoxia/ischemia. Brain Res Rev 2008; 59: 22-33

25. Pallet N, Bouvier N, Legendre C et al. Antiapoptotic properties of recombinant human erythropoietin protects against tubular cyclosporine toxicity. Pharmacol Res 2010; 61: 71-75

26. Wang W, Zhang J. Protective effect of erythropoietin against aristolochic acid-induced apoptosis in renal tubular epithelial cells. Eur J Pharmacol 2008; 588: 135-140

27. Chang YK, Choi DE, Na KR et al. Erythropoietin Attenuates Renal Injury in an Experimental Model of Rat Unilateral Ureteral Obstruction via Anti-Inflammatory and Anti-Apoptotic effects. J Urol 2009; 181: 1434-1443

28. Sekiguchi N, Inoguchi T, Kobayashi K et al. Erythropoietin attenuated high glucose-induced apoptosis in cultured human aortic endothelial cells. Biochem Biophys Res Commun 2005; 34: 218-222

29. Quin C, Xiao Y, Zhong Q et al. Anti-inflammatory effect of erythropoietin pretreatment on cardiomyocytes with hypoxia/reoxygenation injury and the possible mechanism. Chin J Traumatol 2008; 11: 352-358

30. Hirata A, Minamino T, Asanuma H et al. Erythropoietin Enhances Neovascularization of Ischemic Myocardium and Improves Left Ventricular Dysfunction After Myocardial Infarction in Dogs. J Am Coll Cardiol 2006; 48: 176-184

31. Lykissas MG, Sakellariou E, Vekris MD et al. Axonal regeneration stimulated by erythropoietin: An experimental study in rats. J Neurosci Methods 2007; 164: 107-115

32. Vaziri ND. Cardiovascular effects of erythropoietin and anemia correction. Curr Opin Nephrol and Hypertens 2001; 10: 633-637

33. Zhang Z, Barrett JD, Jamgotchian N et al. Recombinant human erythropoietin (rhEPO) stimulates gene transcription of renin angiotensin system and growth factor mRNAs in rat vascular smooth muscle cells [abstract]. J Investig Med 1996; 44: 91

34. Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 1999; 33: 821-828

35. Akimoto T, Kuzano E, Fujita N et al. Erythropoietin modulates angiotensin II-or noradrenaline-induced Ca2+ mobilization in cultured rat vascular smooth-muscle cells. Nephrol Dial Transplant 2001; 16: 491-499

36. Vogel V, Kramer HJ, Bдcker A et al. Effects of Erythropoietin on Endothelin-1 Synthesis and the Cellular Calcium Messenger System in Vascular Endothelial Cells. Am J Hypertens 1997; 10: 289-296

37. Eckardt KU. Erythropoietin and microvascular diabetic complications. Nephrol Dial Transplant 2009; 24: 388-390

38. Nagarajan S, Mansfield E, Hsieh S et al. Transplant reno-vascular stenoses associated with early erythropoietin use. Clin Transplant 2007; 21: 597-608

39. Fuste B, Seradell M, Escolar G et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost 2002; 88: 687-685

40. Kahraman S, Yilmaz R, Kirkpantur A et al. Impact of rhEPO therapy initiation on soluble adhesion molecule levels in haemodialysis patients. Nephrology 2005; 10: 64-69

41. Гуревич КЯ, ред. Человеческий рекомбинантный эритропоэтин (Эпокрин) в лечении анемии (Практическое руководство). ИКФ «Фолиант», СПб., 2001; 45-46

42. Пчелин И. Ю, Шишкин А Н. Механизмы развития и клиническое значение анемии у пациентов с сахарным диабетом 1 и 2 типа. Вестн С.-Петерб ун-та Сер 11 2010; (2): 73-80

43. Kazory A, Ross EA. Anemia: The Point of Convergence or Divergence for Kidney Disease and Heart Failure? J Am Coll Cardiol 2009; 53: 639-647

44. Kleijn L, Boer RA, Voors AA. Should erythropoietin treatment in chronic heart failure be haemoglobin targeted? Eur J Heart Fail 2010; 12: 215-216

45. Goldsmith D, Covic A. Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA). Nephrol Dial Transplant 2010. In press


Для цитирования:


Пчелин И.Ю., Шишкин А.Н., Коробицын Л.П. ПРОБЛЕМА СООТНОШЕНИЯ ПОЛЬЗЫ И РИСКА ТЕРАПИИ СРЕДСТВАМИ, СТИМУЛИРУЮЩИМИ ЭРИТРОПОЭЗ, ПРИ ДИАБЕТИЧЕСКОЙ НЕФРОПАТИИ. Нефрология. 2010;14(3):32-36. https://doi.org/10.24884/1561-6274-2010-14-3-32-36

For citation:


Pchelin I.Yu., Shishkin A.N., Korobitsyn L.P. PROBLEM OF THE THERAPY USE AND RISK RATIO OF THE MEDICATION WHICH STIMULATE ERTHROPOESIS IN DIABETIC NEPHROPATHY. Nephrology (Saint-Petersburg). 2010;14(3):32-36. (In Russ.) https://doi.org/10.24884/1561-6274-2010-14-3-32-36

Просмотров: 42


ISSN 1561-6274 (Print)
ISSN 2541-9439 (Online)